| Name | Title | Contact Details |
|---|
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
NFW is a circularity platform for plastic-free performance materials. NFW follows three Ground Rules in everything we develop: start well, stay clean, end well. While nearly everything in the built world relies on some type of plastic that began as crude oil and that will become plastic pollution, we are establishing a new material reality. We believe all materials should begin and end as nutrients, ready for the next growth cycle—true circularity. Our multi-material platform serves a wide range of industries—from fashion and footwear to automotive and upholstery. NFW technology embeds seamlessly into existing supply chains, enabling the worlds most iconic brands to design and scale products with high-performance, plastic-free materials. NFW makes global brands more sustainable, empowering them to create without plastics. Alongside the boldest brands and visionary designers, we are pioneering a naturally circular, post-oil economy.
Herspiegel is a consulting firm based in Pennsylvania, founded in 2007, that specializes in pharmaceutical and biotech commercialization services. With over fifteen years of experience, the company has supported more than 150 product launches across various therapeutic areas, including primary care, oncology, and rare diseases. Their mission is to create a model for successful pharmaceutical product launches. The firm offers a wide range of services tailored to the life sciences industry, including market access, medical affairs, marketing strategy, and operational execution. Herspiegels team consists of over 350 experts, including MDs, PhDs, MBAs, and pharmacists, who provide deep knowledge to help clients navigate complex challenges and maximize brand potential. They serve a diverse clientele, from startups to large global pharmaceutical companies, focusing on strategic insights and operational excellence to enhance commercial success and patient outcomes. Herspiegel has also expanded its capabilities through strategic acquisitions, such as Decisive Consulting, which enhances their market access and value strategy services. This positions Herspiegel to deliver innovative solutions in a dynamic pharmaceutical landscape.
LG Chem is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials, and life sciences. The company manufactures a wide range of products from high-value added petrochemicals to renewable plastics, specializing in cutting-edge electronic and battery materials such as cathodes, as well as drugs and vaccines to deliver differentiated solutions for its customers. LG Chem is committed to reaching carbon-neutral growth by 2030 and net-zero emissions by 2050 by managing the impacts of climate change and making positive contributions to society through renewable energy and responsible supply chains.
Accelerant is a data-driven risk exchange connecting specialty insurance underwriters with risk capital providers. Founded in 2018 by a group of longtime insurance industry executives and technology experts, our vision is to rebuild the way risk is exchanged – so that it works better, for everyone. For the underwriters we call Members, we deliver a full service offering that includes insights and analytics, distribution management, operational resources, and stable underwriting capacity. Our approach frees our Members to focus on profitable underwriting while growing their businesses. Our portfolio presents attractive, validated, and diversified source of specialty insurance premium to our risk capital provider partners.